New combo therapy shows promise against hard-to-treat t-cell lymphoma

NCT ID NCT03113500

First seen Nov 15, 2025 · Last updated Jun 12, 2026 · Updated 31 times

Summary

This study tested a new treatment for people with a rare blood cancer called CD30-positive peripheral T-cell lymphoma. The treatment combines a targeted drug (brentuximab vedotin) with standard chemotherapy. The goal was to see how well the combination works and what side effects it causes. 48 adults took part, and the study is no longer enrolling new participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BCCA-Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

Conditions

Explore the condition pages connected to this study.